PMID- 26191056
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150720
LR  - 20200930
IS  - 1664-302X (Print)
IS  - 1664-302X (Electronic)
IS  - 1664-302X (Linking)
VI  - 6
DP  - 2015
TI  - CD4:CD8 lymphocyte ratio as a quantitative measure of immunologic health in HIV-1 
      infection: findings from an African cohort with prospective data.
PG  - 670
LID - 10.3389/fmicb.2015.00670 [doi]
LID - 670
AB  - In individuals with human immunodeficiency virus type 1 (HIV-1) infection, 
      CD4:CD8 lymphocyte ratio is often recognized as a quantitative outcome that 
      reflects the critical role of both CD4(+) and CD8(+) T-cells in HIV-1 
      pathogenesis or disease progression. Our work aimed to first establish the 
      dynamics and clinical relevance of CD4:CD8 ratio in a cohort of native Africans 
      and then to examine its association with viral and host factors, including: (i) 
      length of infection, (ii) demographics, (iii) HIV-1 viral load (VL), (iv) change 
      in CD4(+) T-lymphocyte count (CD4 slope), (v) HIV-1 subtype, and (vi) host 
      genetics, especially human leukocyte antigen (HLA) variants. Data from 499 HIV-1 
      seroconverters with frequent (monthly to quarterly) follow-up revealed that 
      CD4:CD8 ratio was stable in the first 3 years of infection, with a modest 
      correlation with VL and CD4 slope. A relatively normal CD4:CD8 ratio (>1.0) in 
      early infection was associated with a substantial delay in disease progression to 
      severe immunodeficiency (<350 CD4 cells/mul), regardless of other correlates of 
      HIV-1 pathogenesis (adjusted hazards ratio (HR) = 0.43, 95% confidence interval 
      (CI) = 0.29-0.63, P < 0.0001). Low VL (<10,000 copies/ml) and HLA-A*74:01 were 
      the main predictors of CD4:CD8 ratio >1.0, but HLA variants (e.g., HLA-B*57 and 
      HLA-B*81) previously associated with VL and/or CD4 trajectories in eastern and 
      southern Africans had no obvious impact on CD4:CD8 ratio. Collectively, these 
      findings suggest that CD4:CD8 ratio is a robust measure of immunologic health 
      with both clinical and epidemiological implications.
FAU - Tang, Jianming
AU  - Tang J
AD  - Department of Medicine, University of Alabama at Birmingham, Birmingham, AL USA.
FAU - Li, Xuelin
AU  - Li X
AD  - Department of Medicine, University of Alabama at Birmingham, Birmingham, AL USA.
FAU - Price, Matthew A
AU  - Price MA
AD  - International AIDS Vaccine Initiative, New York, NY USA ; Department of 
      Epidemiology & Biostatistics, University of California, San Francisco, San 
      Francisco, CA USA.
FAU - Sanders, Eduard J
AU  - Sanders EJ
AD  - Centre for Geographic Medicine Research, Kenya Medical Research Institute, Kilifi 
      Kenya ; Centre for Clinical Vaccinology and Tropical Medicine, University of 
      Oxford, Oxford UK.
FAU - Anzala, Omu
AU  - Anzala O
AD  - Kenya AIDS Vaccine Initiative, Nairobi Kenya.
FAU - Karita, Etienne
AU  - Karita E
AD  - Projet San Francisco, Kigali Rwanda.
FAU - Kamali, Anatoli
AU  - Kamali A
AD  - Uganda Virus Research Unit on AIDS, Medical Research Council/Uganda Virus 
      Research Institute, Masaka Uganda.
FAU - Lakhi, Shabir
AU  - Lakhi S
AD  - Zambia-Emory HIV Research Project, Lusaka Zambia.
FAU - Allen, Susan
AU  - Allen S
AD  - Zambia-Emory HIV Research Project, Lusaka Zambia ; Department of Pathology and 
      Laboratory Medicine, Emory University, Atlanta, GA USA.
FAU - Hunter, Eric
AU  - Hunter E
AD  - Emory Vaccine Center, Emory University, Atlanta, GA USA.
FAU - Kaslow, Richard A
AU  - Kaslow RA
AD  - Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL 
      USA.
FAU - Gilmour, Jill
AU  - Gilmour J
AD  - International AIDS Vaccine Initiative, Human Immunology Laboratory, Chelsea and 
      Westminster Hospital, London UK.
LA  - eng
GR  - 092654/Wellcome Trust/United Kingdom
GR  - D43 TW001042/TW/FIC NIH HHS/United States
GR  - R01 AI064060/AI/NIAID NIH HHS/United States
GR  - R01 AI071906/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20150701
PL  - Switzerland
TA  - Front Microbiol
JT  - Frontiers in microbiology
JID - 101548977
PMC - PMC4486831
OTO - NOTNLM
OT  - Africa
OT  - CD4:CD8 ratio
OT  - HIV-1
OT  - HLA
OT  - statistical models
OT  - subtype
OT  - viral load
EDAT- 2015/07/21 06:00
MHDA- 2015/07/21 06:01
PMCR- 2015/07/01
CRDT- 2015/07/21 06:00
PHST- 2015/04/22 00:00 [received]
PHST- 2015/06/19 00:00 [accepted]
PHST- 2015/07/21 06:00 [entrez]
PHST- 2015/07/21 06:00 [pubmed]
PHST- 2015/07/21 06:01 [medline]
PHST- 2015/07/01 00:00 [pmc-release]
AID - 10.3389/fmicb.2015.00670 [doi]
PST - epublish
SO  - Front Microbiol. 2015 Jul 1;6:670. doi: 10.3389/fmicb.2015.00670. eCollection 
      2015.